Sentence examples for escalating phase from inspiring English sources

The study was conducted as a single-blind, randomized, dose escalating Phase 1 clinical trial in healthy volunteers, designed to evaluate the safety, reactogenicity, and immunogenicity of the AMA1-C1 vaccine formulated on Alhydrogel® and mixed with CPG 7909.

In this dose escalating phase I study, the pharmacodynamic effect of PTK787/ZK222584 (PTK/ZK), an orally active inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, which inhibits VEGF-mediated angiogenesis, was evaluated.

This was an open-label, single center, non-randomized, dose escalating phase I study.

In a randomized, double-blind, placebo-controlled, dose escalating Phase I study (NCT00771420), Burmester et al 26 evaluated the safety, tolerability, and pharmacoki-netic and pharmacodynamic profiles of mavrilimumab in 32 subjects with mild to moderate RA (DAS28 ≤4.8) of ≥6 months duration and who had received a stable dose of MTX for ≥3 months.

The operation itself was divided into steadily escalating phases, mapped out in advance.

We assessed the safety and immunogenicity of recombinant PfAMA1 in a dose-escalating, phase Ia trial.

Tremelimumab was tested in a classical dose-escalating phase I trial [39].

We have designed a 3+3 dose-escalating phase I trial with a fixed dose of MC (50 mg two times daily) plus IM (400 mg per day; 300 and 400 mg two times daily).

PF-3512676 CPG-79099, ProMune®) is a TLR-9 activating oligodeoxynucleotide and potent plasmacytoid dendritic cell stimulator 163 that was recently shown in a dose-escalating Phase I trial to induce an ORR in 32% of patients (three complete responses, six partial responses) with treatment-refractory stage IB to IVA CTCL.

In a dose-escalating Phase I study, imatinib-resistant CML patients in the chronic phase (17 patients), accelerated phase (46 patients) and blast crisis (33 patients), together with 13 Ph+ ALL patients, were treated with AMN107 (50–1200 mg day−1) for up to 385 days (Kantarjian et al, 2006).

In this context, a multi\e dose-escalating phase I trial to determine the phase II recommended dose of this combination, to determine the impact of oral MC on the IM pharmacokinetic (PK) and to seek some signs of activity in patients with IM and sunitinib-refractory GIST, with chordoma, life-threatening aggressive fibromatosis or melanoma harbouring KIT mutation was conducted.